Gastroenterology | IND Enabling Drugs

Plakous Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

Chinaplas 2020

Participation Not Confirmed

Update your events

Plakous Therapeutics Awarded $1.7 Million Fast-Track SBIR Grant from NIH to Develop Therapies for Necrotizing Enterocolitis

Lead Product(s): Protego-PD

Therapeutic Area: Gastroenterology Product Name: Protego-PD

Highest Development Status: IND Enabling Product Type: Large molecule

Partner/Sponsor/Collaborator: National Institute of Health

Deal Size: $1.7 million Upfront Cash: Undisclosed

Deal Type: Funding July 08, 2020

Details:

This award will fund the potency and preclinical effectiveness milestones for an Investigational New Drug (IND) filing for Protego-PDTM, an orally delivered acellular biotherapeutic developed by Plakous from post-delivery placentas.

Synthetic Biologics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

Chinaplas 2020

Participation Not Confirmed

Update your events

Synthetic Biologics Seeks US FDA Approval to Initiate Phase 1 Study of SYN-020 Intestinal Alkaline Phosphatase

Lead Product(s): Recombinant bovine intestinal alkaline phosphatase

Therapeutic Area: Gastroenterology Product Name: SYN-020

Highest Development Status: IND Enabling Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 30, 2020

Details:

Under the IND application, the Company intends to conduct a Phase 1 single ascending dose study in healthy volunteers, designed to evaluate SYN-020 for safety, tolerability, and pharmacokinetic parameters.

Xiling Lab

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CHINA China

Post An Enquiry

Virtual Booth

Chinaplas 2020

Participation Not Confirmed

Update your events

Scimount Announces FDA Approval of SMP-100's IND Application for the Treatment of Irritable Bowel Syndrome

Lead Product(s): SMP-100

Therapeutic Area: Gastroenterology Product Name: Undisclosed

Highest Development Status: IND Enabling Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 14, 2020

Details:

First randomized, double-blinded, placebo-controlled Phase I clinical trial to investigate the safety and pharmacokinetics after oral administration of SMP-100 in healthy volunteers.